Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH: zilebesiran in high-risk or established cardiovascular disease hypertension
NL-OMON60687Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) comparing zilebesiran with placebo (2 arms). Primary endpoint: Time to first occurrence of major cardiovascular composite. Started Mar 2026; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON60687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60687.